Toray Develops Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases
Toray has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This enables the selective adsorption of large-molecule pathogenic substances. The technology aims to provide new blood purification treatment options for intractable diseases.
📋 Article Processing Timeline
- 📰 Published: March 26, 2026 at 23:34
- 🔍 Collected: March 28, 2026 at 21:59 (46h 24m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 03:22 (413h 23m after Collected)
Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers within a wide range from several nm to approximately 1,000nm. This breakthrough allows for the selective adsorption of pathogenic substances associated with intractable diseases such as autoimmune disorders, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer. By utilizing advanced analysis and digital simulation, Toray has achieved significantly larger pore sizes while maintaining fiber strength. The company is advancing the design and mass production technology for various disease treatments, aiming for early practical application and potential expansion into biopharmaceutical manufacturing.
FAQ
What diseases is this technology applicable to?
It is intended for intractable diseases such as autoimmune disorders, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer.
How does it differ from conventional fibers?
It can control pore sizes up to approximately 1,000nm, enabling the removal of large-molecule pathogenic substances that conventional fibers could not capture.